Bookmark and Share
BioAssay: AID 2180

Modulation of Metabotropic Glutmate Receptor mGluR4: Human PAM Fold-Shift

The primary pathophysiological change giving rise to the symptoms of Parkinson's disease (PD) is a loss of the dopaminergic neurons in the substantia nigra pars compacta (SNc) that are involved in modulating the function of basal ganglia (BG) nuclei. Unfortunately, traditional therapies for treatment of PD based on dopamine replacement strategies eventually fail in most patients and are more ..
_
   
 Tested Compounds
 Tested Compounds
All(9)
 
 
Active(7)
 
 
Inactive(2)
 
 
 Tested Substances
 Tested Substances
All(9)
 
 
Active(7)
 
 
Inactive(2)
 
 
AID: 2180
Data Source: Vanderbilt Screening Center for GPCRs, Ion Channels and Transporters (human mGluR4 fold shift)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2009-12-07

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 7
Related Experiments
Show more
AIDNameTypeProbeComment
2437Modulation of the Metabotropic Glutamate Receptor mGluR4Summary1 depositor-specified cross reference
2807Modulation of the Metabotropic Glutamate Receptor mGluR4: Calcium AssayConfirmatory depositor-specified cross reference
2179Modulation of Metabotropic Glutamate Receptor mGluR4: Rat PAM Fold-ShiftConfirmatory same project related to Summary assay
2181Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR8Confirmatory same project related to Summary assay
2182Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR7Confirmatory same project related to Summary assay
2183Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR4Confirmatory same project related to Summary assay
2185Modulation of the Metabotropic Glutamate Receptor mGluR4: Rat PAM PotencyConfirmatory same project related to Summary assay
2188Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR2Confirmatory same project related to Summary assay
2190Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR3Confirmatory same project related to Summary assay
2191Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR6Confirmatory same project related to Summary assay
2193Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR1Confirmatory same project related to Summary assay
2197Modulation of the Metabotropic Glutamate Receptor mGluR4: Potency at human mGluR4Confirmatory same project related to Summary assay
2199Modulation of the Metabotropic Glutamate Receptor mGluR4: Selectivity at mGluR5Confirmatory same project related to Summary assay
488971Rat PAM Fold-shift Assay with mGluR4 GIRKConfirmatory same project related to Summary assay
Description:
Assay Provider: Colleen Niswender
Assay Provider Affiliation: Vanderbilt University

The primary pathophysiological change giving rise to the symptoms of Parkinson's disease (PD) is a loss of the dopaminergic neurons in the substantia nigra pars compacta (SNc) that are involved in modulating the function of basal ganglia (BG) nuclei. Unfortunately, traditional therapies for treatment of PD based on dopamine replacement strategies eventually fail in most patients and are associated with numerous side effects. A great deal of effort has been focused on developing a detailed understanding of the circuitry and function of the BG to develop novel, nondopaminergic, approaches for restoring normal BG function in PD patients. Exciting advances suggest that metabotropic glutamate receptors (mGluRs), including the group III mGluRs (mGluR4, -7 and -8), play important roles in regulating transmission through the BG and could serve as targets for novel PD therapeutics (Conn et al., 2005). For instance, mGluR4 activation reduces overactive GABA release at a specific inhibitory BG synapse (Macinnes and Duty, 2008; Marino et al., 2003; Valenti et al., 2003) and reverses motor deficits in a variety of rodent PD models (Konieczny et al., 2007; MacInnes et al., 2004; Marino et al., 2003; Ossowska et al., 2007; Valenti et al., 2003).

To more selectively activate mGluR4 and improve upon the pharmacokinetic liabilities of glutamate analogs, we and others have developed novel positive allosteric modulators (PAMs) which potentiate glutamate function at mGluR4 (Engers et al., 2009; Maj et al., 2003; Marino et al., 2003; Niswender et al., 2008a; Niswender et al., 2008b; Williams et al., 2008); several of these tool compounds exhibit antiparkinsonian and neuroprotective effects in multiple rodent PD models (Battaglia et al., 2006; Marino et al., 2003; Niswender et al., 2008a). Unfortunately, many available compounds have lacked pharmacokinetic properties to make them useful tools for study of mGluR4 function via systemic routes of administration. The probe compound developed here exhibits sufficient potency, efficacy, and pharmacokinetic properties, including brain penetration, to make it a useful compound to progress mGluR4 biology, which will undoubtedly allow the intense study of mGluR4 activation in multiple areas of neuroscience such as psychiatric disorders (Stachowicz et al., 2006; Stachowicz et al., 2004), cancer (Iacovelli et al., 2006), and addiction (Blednov et al., 2004).



References
1. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Traficante A, Nicoletti F and Bruno V (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26(27):7222-7229.
2. Blednov YA, Walker D, Osterndorf-Kahanek E and Harris RA (2004) Mice lacking metabotropic glutamate receptor 4 do not show the motor stimulatory effect of ethanol. Alcohol 34(2-3):251-259.
3. Conn PJ, Battaglia G, Marino MJ and Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6(10):787-798.
4. Engers DW, Niswender CM, Weaver CD, Jadhav S, Menon UN, Zamorano R, Conn PJ, Lindsley CW and Hopkins CR (2009) Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem 52(14):4115-4118.
5. Iacovelli L, Arcella A, Battaglia G, Pazzaglia S, Aronica E, Spinsanti P, Caruso A, De Smaele E, Saran A, Gulino A, D'Onofrio M, Giangaspero F and Nicoletti F (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci 26(32):8388-8397.
6. Konieczny J, Wardas J, Kuter K, Pilc A and Ossowska K (2007) The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience 145(2):611-620.
7. Macinnes N and Duty S (2008) Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo. Eur J Pharmacol 580(1-2):95-99.
8. MacInnes N, Messenger MJ and Duty S (2004) Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol 141(1):15-22.
9. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F and Flor PJ (2003) (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45(7):895-906.
10. Marino MJ, Williams DL, Jr., O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG and Conn PJ (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A 100(23):13668-13673.
11. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW and Conn PJ (2008a) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 74(5):1345-1358.
12. Niswender CM, Lebois EP, Luo Q, Kim K, Muchalski H, Yin H, Conn PJ and Lindsley CW (2008b) Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg Med Chem Lett 18(20):5626-5630.
13. Ossowska K, Konieczny J, Wardas J, Pietraszek M, Kuter K, Wolfarth S and Pilc A (2007) An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 32(2):179-188.
14. Stachowicz K, Chojnacka-Wojcik E, Klak K and Pilc A (2006) Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Pharmacol Rep 58(6):820-826.
15. Stachowicz K, Klak K, Klodzinska A, Chojnacka-Wojcik E and Pilc A (2004) Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. Eur J Pharmacol 498(1-3):153-156.
16. Valenti O, Marino MJ, Wittmann M, Lis E, DiLella AG, Kinney GG and Conn PJ (2003) Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci 23(18):7218-7226.
17. Williams R, Niswender CM, Luo Q, Le U, Conn PJ and Lindsley CW (2008) Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett.
Protocol
Cell line creation and culture of the human mGluR4/ Gqi5/CHO line. Human mGluR4 (hmGluR4)/CHO cells were stably transfected with the chimeric G protein Gqi5 (Conklin et al., 1993) in pIRESneo3 (Invitrogen, Carlsbad, CA) and single neomycin-resistant clones were isolated and screened for mGluR4-mediated calcium mobilization using the method described below. hmGluR4/CHO cells were cultured in 90 percent Dulbecco's Modified Eagle Media (DMEM), 10 percent dialyzed fetal bovine serum (FBS), 100 units/ml penicillin/streptomycin, 20 mM HEPES (pH 7.3), 1 mM sodium pyruvate, 20 ug/ml proline, 2 mM glutamine, 400 ug/ml G418 sufate (Mediatech, Inc., Herndon, VA) and 5 nM methotrexate (Calbiochem, EMD Chemicals, Gibbstown, NJ). All cell culture reagents were purchased from Invitrogen Corp. (Carlsbad, CA) unless otherwise noted.

Fold shift determinations. Assays were performed within Vanderbilt University's High-Throughput Screening Center. Human mGluR4/CHO cells (30,000 cells/20 ul/well) were plated in black-walled, clear-bottomed, TC treated, 384 well plates (Greiner Bio-One, Monroe, North Carolina) in DMEM containing 10 percent dialyzed FBS, 20 mM HEPES, 100 units/ml penicillin/streptomycin, and 1 mM sodium pyruvate (Plating Medium). The cells were grown overnight at 37 degrees C in the presence of 5 percent CO2. The next day, the medium was removed and replaced with 20 uL of 1 uM Fluo-4, AM (Invitrogen, Carlsbad, CA) prepared as a 2.3 mM stock in DMSO and mixed in a 1:1 ratio with 10 percent (w/v) pluronic acid F-127 and diluted in Assay Buffer (Hank's balanced salt solution, 20 mM HEPES and 2.5 mM Probenecid (Sigma-Aldrich, St. Louis, MO)) for 45 minutes at 37 degrees C. Dye was removed and replaced with 20 uL of Assay Buffer. Test compounds were transferred to daughter plates using an Echo acoustic plate reformatter (Labcyte, Sunnyvale, CA) and then diluted into Assay Buffer to generate a 20 uM stock. Ca2+ flux was measured using the Functional Drug Screening System 6000 (FDSS6000, Hamamatsu, Japan). Baseline readings were taken (10 images at 1 Hz, excitation, 47+/-20 nm, emission, 540+/-30 nm) and then 20 ul/well test compounds were added using the FDSS's integrated pipettor. Cells were incubated with test compounds (final concentration 30 uM) for 2.5 minutes and then increasing concentrations of glutamate were applied. FDSS data were analyzed using a custom analysis application.

For fold shift experiments, 20 ul of test compound (2X concentration, 30 uM final concentration) was applied approximately 2.5 minutes prior to increasing concentrations of glutamate (10 ul of a 5x final concentration). Curves were fitted using a four point logistical equation using Microsoft XLfit (IDBS, Bridgewater, NJ). Subsequent confirmations of concentration-response parameters were performed using independent serial dilutions of source compounds and data from multiple days experiments were integrated and fit using a four point logistical equation in GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).

For compounds that changed the EC50 of glutamate 3 fold or less, 'Outcome' was assigned as 'Inactive' and 'Score' was assigned as '1'. For compounds that changed the EC50 of glutamate greater than 3 fold, 'Outcome' was assigned as 'Active'. 'Score' was assigned as '50' for those with a fold-shift less than or equal to 10 or as '100' for those with a fold-shift greater than 10.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Rep1ForExperiment1_0.0000155_uM (1.55e-05μM**)Value for replicate 1 for experiment 1 at 0.0000155 uMFloat
2Rep2ForExperiment1_0.0000155_uM (1.55e-05μM**)Value for replicate 2 for experiment 1 at 0.0000155 uMFloat
3Rep1ForExperiment1_0.000156_uM (0.000156μM**)Value for replicate 1 for experiment 1 at 0.000156 uMFloat
4Rep2ForExperiment1_0.000156_uM (0.000156μM**)Value for replicate 2 for experiment 1 at 0.000156 uMFloat
5Rep1ForExperiment1_0.00156_uM (0.00156μM**)Value for replicate 1 for experiment 1 at 0.00156 uMFloat
6Rep2ForExperiment1_0.00156_uM (0.00156μM**)Value for replicate 2 for experiment 1 at 0.00156 uMFloat
7Rep1ForExperiment1_0.00900_uM (0.009μM**)Value for replicate 1 for experiment 1 at 0.00900 uMFloat
8Rep2ForExperiment1_0.00900_uM (0.009μM**)Value for replicate 2 for experiment 1 at 0.00900 uMFloat
9Rep1ForExperiment1_0.0624_uM (0.0624μM**)Value for replicate 1 for experiment 1 at 0.0624 uMFloat
10Rep2ForExperiment1_0.0624_uM (0.0624μM**)Value for replicate 2 for experiment 1 at 0.0624 uMFloat
11Rep1ForExperiment1_0.394_uM (0.394μM**)Value for replicate 1 for experiment 1 at 0.394 uMFloat
12Rep2ForExperiment1_0.394_uM (0.394μM**)Value for replicate 2 for experiment 1 at 0.394 uMFloat
13Rep1ForExperiment1_2.49_uM (2.49μM**)Value for replicate 1 for experiment 1 at 2.49 uMFloat
14Rep2ForExperiment1_2.49_uM (2.49μM**)Value for replicate 2 for experiment 1 at 2.49 uMFloat
15Rep1ForExperiment1_15.7_uM (15.7μM**)Value for replicate 1 for experiment 1 at 15.7 uMFloat
16Rep2ForExperiment1_15.7_uM (15.7μM**)Value for replicate 2 for experiment 1 at 15.7 uMFloat
17Rep1ForExperiment1_100_uM (100μM**)Value for replicate 1 for experiment 1 at 100 uMFloat
18Rep2ForExperiment1_100_uM (100μM**)Value for replicate 2 for experiment 1 at 100 uMFloat
19Rep1ForExperiment1_1000_uM (1000μM**)Value for replicate 1 for experiment 1 at 1000 uMFloat
20Rep2ForExperiment1_1000_uM (1000μM**)Value for replicate 2 for experiment 1 at 1000 uMFloat
21AverageForExperiment1_0.0000155uMAverage for experiment 1 at 0.0000155 uMFloat
22AverageForExperiment1_0.000156uMAverage for experiment 1 at 0.000156 uMFloat
23AverageForExperiment1_0.00156uMAverage for experiment 1 at 0.00156 uMFloat
24AverageForExperiment1_0.00900uMAverage for experiment 1 at 0.00900 uMFloat
25AverageForExperiment1_0.0624uMAverage for experiment 1 at 0.0624 uMFloat
26AverageForExperiment1_0.394uMAverage for experiment 1 at 0.394 uMFloat
27AverageForExperiment1_2.49uMAverage for experiment 1 at 2.49 uMFloat
28AverageForExperiment1_15.7uMAverage for experiment 1 at 15.7 uMFloat
29AverageForExperiment1_100uMAverage for experiment 1 at 100 uMFloat
30AverageForExperiment1_1000uMAverage for experiment 1 at 1000 uMFloat
31StddevForExperiment1_0.0000155uMStandard deviation for experiment 1 at 0.0000155 uMFloat
32StddevForExperiment1_0.000156uMStandard deviation for experiment 1 at 0.000156 uMFloat
33StddevForExperiment1_0.00156uMStandard deviation for experiment 1 at 0.00156 uMFloat
34StddevForExperiment1_0.00900uMStandard deviation for experiment 1 at 0.00900 uMFloat
35StddevForExperiment1_0.0624uMStandard deviation for experiment 1 at 0.0624 uMFloat
36StddevForExperiment1_0.394uMStandard deviation for experiment 1 at 0.394 uMFloat
37StddevForExperiment1_2.49uMStandard deviation for experiment 1 at 2.49 uMFloat
38StddevForExperiment1_15.7uMStandard deviation for experiment 1 at 15.7 uMFloat
39StddevForExperiment1_100uMStandard deviation for experiment 1 at 100 uMFloat
40StddevForExperiment1_1000uMStandard deviation for experiment 1 at 1000 uMFloat
41GluPotencyExperiment1Glutamate potency for experiment 1Float
42GluFoldShiftExperiment1Glutamate fold shift for experiment 1Float
43Rep1ForExperiment2_0.0000155_uM (1.55e-05μM**)Value for replicate 1 for experiment 2 at 0.0000155 uMFloat
44Rep2ForExperiment2_0.0000155_uM (1.55e-05μM**)Value for replicate 2 for experiment 2 at 0.0000155 uMFloat
45Rep1ForExperiment2_0.000156_uM (0.000156μM**)Value for replicate 1 for experiment 2 at 0.000156 uMFloat
46Rep2ForExperiment2_0.000156_uM (0.000156μM**)Value for replicate 2 for experiment 2 at 0.000156 uMFloat
47Rep1ForExperiment2_0.00156_uM (0.00156μM**)Value for replicate 1 for experiment 2 at 0.00156 uMFloat
48Rep2ForExperiment2_0.00156_uM (0.00156μM**)Value for replicate 2 for experiment 2 at 0.00156 uMFloat
49Rep1ForExperiment2_0.00900_uM (0.009μM**)Value for replicate 1 for experiment 2 at 0.00900 uMFloat
50Rep2ForExperiment2_0.00900_uM (0.009μM**)Value for replicate 2 for experiment 2 at 0.00900 uMFloat
51Rep1ForExperiment2_0.0624_uM (0.0624μM**)Value for replicate 1 for experiment 2 at 0.0624 uMFloat
52Rep2ForExperiment2_0.0624_uM (0.0624μM**)Value for replicate 2 for experiment 2 at 0.0624 uMFloat
53Rep1ForExperiment2_0.394_uM (0.394μM**)Value for replicate 1 for experiment 2 at 0.394 uMFloat
54Rep2ForExperiment2_0.394_uM (0.394μM**)Value for replicate 2 for experiment 2 at 0.394 uMFloat
55Rep1ForExperiment2_2.49_uM (2.49μM**)Value for replicate 1 for experiment 2 at 2.49 uMFloat
56Rep2ForExperiment2_2.49_uM (2.49μM**)Value for replicate 2 for experiment 2 at 2.49 uMFloat
57Rep1ForExperiment2_15.7_uM (15.7μM**)Value for replicate 1 for experiment 2 at 15.7 uMFloat
58Rep2ForExperiment2_15.7_uM (15.7μM**)Value for replicate 2 for experiment 2 at 15.7 uMFloat
59Rep1ForExperiment2_100_uM (100μM**)Value for replicate 1 for experiment 2 at 100 uMFloat
60Rep2ForExperiment2_100_uM (100μM**)Value for replicate 2 for experiment 2 at 100 uMFloat
61Rep1ForExperiment2_1000_uM (1000μM**)Value for replicate 1 for experiment 2 at 1000 uMFloat
62Rep2ForExperiment2_1000_uM (1000μM**)Value for replicate 2 for experiment 2 at 1000 uMFloat
63AverageForExperiment2_0.0000155uMAverage for experiment 2 at 0.0000155 uMFloat
64AverageForExperiment2_0.000156uMAverage for experiment 2 at 0.000156 uMFloat
65AverageForExperiment2_0.00156uMAverage for experiment 2 at 0.00156 uMFloat
66AverageForExperiment2_0.00900uMAverage for experiment 2 at 0.00900 uMFloat
67AverageForExperiment2_0.0624uMAverage for experiment 2 at 0.0624 uMFloat
68AverageForExperiment2_0.394uMAverage for experiment 2 at 0.394 uMFloat
69AverageForExperiment2_2.49uMAverage for experiment 2 at 2.49 uMFloat
70AverageForExperiment2_15.7uMAverage for experiment 2 at 15.7 uMFloat
71AverageForExperiment2_100uMAverage for experiment 2 at 100 uMFloat
72AverageForExperiment2_1000uMAverage for experiment 2 at 1000 uMFloat
73StddevForExperiment2_0.0000155uMStandard deviation for experiment 2 at 0.0000155 uMFloat
74StddevForExperiment2_0.000156uMStandard deviation for experiment 2 at 0.000156 uMFloat
75StddevForExperiment2_0.00156uMStandard deviation for experiment 2 at 0.00156 uMFloat
76StddevForExperiment2_0.00900uMStandard deviation for experiment 2 at 0.00900 uMFloat
77StddevForExperiment2_0.0624uMStandard deviation for experiment 2 at 0.0624 uMFloat
78StddevForExperiment2_0.394uMStandard deviation for experiment 2 at 0.394 uMFloat
79StddevForExperiment2_2.49uMStandard deviation for experiment 2 at 2.49 uMFloat
80StddevForExperiment2_15.7uMStandard deviation for experiment 2 at 15.7 uMFloat
81StddevForExperiment2_100uMStandard deviation for experiment 2 at 100 uMFloat
82StddevForExperiment2_1000uMStandard deviation for experiment 2 at 1000 uMFloat
83GluPotencyExperiment2Glutamate potency for experiment 2Float
84GluFoldShiftExperiment2Glutamate fold shift for experiment 2Float
85Rep1ForExperiment3_0.00100_uM (0.001μM**)Value for replicate 1 for experiment 3 at 0.00100 uMFloat
86Rep2ForExperiment3_0.00100_uM (0.001μM**)Value for replicate 2 for experiment 3 at 0.00100 uMFloat
87Rep1ForExperiment3_0.0100_uM (0.01μM**)Value for replicate 1 for experiment 3 at 0.0100 uMFloat
88Rep2ForExperiment3_0.0100_uM (0.01μM**)Value for replicate 2 for experiment 3 at 0.0100 uMFloat
89Rep1ForExperiment3_0.100_uM (0.1μM**)Value for replicate 1 for experiment 3 at 0.100 uMFloat
90Rep2ForExperiment3_0.100_uM (0.1μM**)Value for replicate 2 for experiment 3 at 0.100 uMFloat
91Rep1ForExperiment3_0.316_uM (0.316μM**)Value for replicate 1 for experiment 3 at 0.316 uMFloat
92Rep2ForExperiment3_0.316_uM (0.316μM**)Value for replicate 2 for experiment 3 at 0.316 uMFloat
93Rep1ForExperiment3_1.00_uM (1μM**)Value for replicate 1 for experiment 3 at 1.00 uMFloat
94Rep2ForExperiment3_1.00_uM (1μM**)Value for replicate 2 for experiment 3 at 1.00 uMFloat
95Rep1ForExperiment3_3.16_uM (3.16μM**)Value for replicate 1 for experiment 3 at 3.16 uMFloat
96Rep2ForExperiment3_3.16_uM (3.16μM**)Value for replicate 2 for experiment 3 at 3.16 uMFloat
97Rep1ForExperiment3_10.0_uM (10μM**)Value for replicate 1 for experiment 3 at 10.0 uMFloat
98Rep2ForExperiment3_10.0_uM (10μM**)Value for replicate 2 for experiment 3 at 10.0 uMFloat
99Rep1ForExperiment3_31.6_uM (31.6μM**)Value for replicate 1 for experiment 3 at 31.6 uMFloat
100Rep2ForExperiment3_31.6_uM (31.6μM**)Value for replicate 2 for experiment 3 at 31.6 uMFloat
101Rep1ForExperiment3_100_uM (100μM**)Value for replicate 1 for experiment 3 at 100 uMFloat
102Rep2ForExperiment3_100_uM (100μM**)Value for replicate 2 for experiment 3 at 100 uMFloat
103Rep1ForExperiment3_1000_uM (1000μM**)Value for replicate 1 for experiment 3 at 1000 uMFloat
104Rep2ForExperiment3_1000_uM (1000μM**)Value for replicate 2 for experiment 3 at 1000 uMFloat
105AverageForExperiment3_0.00100uMAverage for experiment 3 at 0.00100 uMFloat
106AverageForExperiment3_0.0100uMAverage for experiment 3 at 0.0100 uMFloat
107AverageForExperiment3_0.100uMAverage for experiment 3 at 0.100 uMFloat
108AverageForExperiment3_0.316uMAverage for experiment 3 at 0.316 uMFloat
109AverageForExperiment3_1.00uMAverage for experiment 3 at 1.00 uMFloat
110AverageForExperiment3_3.16uMAverage for experiment 3 at 3.16 uMFloat
111AverageForExperiment3_10.0uMAverage for experiment 3 at 10.0 uMFloat
112AverageForExperiment3_31.6uMAverage for experiment 3 at 31.6 uMFloat
113AverageForExperiment3_100uMAverage for experiment 3 at 100 uMFloat
114AverageForExperiment3_1000uMAverage for experiment 3 at 1000 uMFloat
115StddevForExperiment3_0.00100uMStandard deviation for experiment 3 at 0.00100 uMFloat
116StddevForExperiment3_0.0100uMStandard deviation for experiment 3 at 0.0100 uMFloat
117StddevForExperiment3_0.100uMStandard deviation for experiment 3 at 0.100 uMFloat
118StddevForExperiment3_0.316uMStandard deviation for experiment 3 at 0.316 uMFloat
119StddevForExperiment3_1.00uMStandard deviation for experiment 3 at 1.00 uMFloat
120StddevForExperiment3_3.16uMStandard deviation for experiment 3 at 3.16 uMFloat
121StddevForExperiment3_10.0uMStandard deviation for experiment 3 at 10.0 uMFloat
122StddevForExperiment3_31.6uMStandard deviation for experiment 3 at 31.6 uMFloat
123StddevForExperiment3_100uMStandard deviation for experiment 3 at 100 uMFloat
124StddevForExperiment3_1000uMStandard deviation for experiment 3 at 1000 uMFloat
125GluPotencyExperiment3Glutamate potency for experiment 3Float
126GluFoldShiftExperiment3Glutamate fold shift for experiment 3Float
127AvgGluPotency*Average glutamate potencyFloatμM
128StddevGluPotencyStandard deviation for glutamate potencyFloat
129SEMGluPotencySEM for glutamate potencyFloat
130AvgGluFoldShiftAverage glutamate fold shiftFloat
131StddevGluFoldShiftStandard deviation for glutamate fold shiftFloat
132SEMGluFoldShiftSEM for glutamate fold shiftFloat

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: NS053536

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: